Dr Mark Feinberg, President and CEO of the International Aids Vaccine Initiative (IAVI), recently visited Nairobi to engage with Kenyan health officials and scientific institutions about vaccine research and development.
With over four decades dedicated to HIV vaccine research, Feinberg expressed renewed optimism about developing an effective HIV vaccine, citing recent advances in inducing broadly neutralising antibodies that target vulnerable regions of the virus. Early clinical trials, many conducted in partnership with Kenyan institutions such as the Kenya AIDS Vaccine Initiative Institute of Clinical Research (KAVI-ICR) and the Kenya Medical Research Institute (Kemri), have shown promising results.
Kenya’s Growing Scientific Capacity
Feinberg praised Kenya’s scientific community for its talent and commitment, highlighting nearly 30 years of collaboration between IAVI and Kenyan partners. He emphasized the importance of expanding Kenya’s role from research to product development, aiming for vaccines and drugs that meet regulatory standards locally and internationally.
"Kenya has capable experts, and the challenge is to elevate their leadership in combating infectious diseases," Feinberg said, noting the country’s ambition to build self-sufficiency in vaccine production.
Supporting Local Manufacturing and Regional Partnerships
During his visit, Feinberg met with Health Cabinet Secretary Aden Duale and representatives from the Kenya BioVax Institute, discussing opportunities to strengthen biomedical innovation and vaccine manufacturing. IAVI is committed to sharing expertise to help Kenyan developers and manufacturers enhance their capabilities.
Feinberg also highlighted ongoing collaborations with African partners, including the Institut Pasteur de Dakar in Senegal, to facilitate vaccine production on the continent. He stressed that achieving regional manufacturing will require sustained investment but remains optimistic about Africa’s potential.
Focus on Public Health Impact
Unlike profit-driven pharmaceutical companies, IAVI prioritizes vaccines that address diseases disproportionately affecting low- and middle-income countries. Feinberg explained that IAVI’s investment decisions are guided by public health needs, vaccine feasibility, and alignment with their scientific expertise.
He reaffirmed IAVI’s commitment to affordable and sustainable access to vaccines, aligning with Kenya’s goals to expand local manufacturing and improve health security.
